Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 10

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 10
---
 statement and annual report, to multiple stockholders who share the same address unless we receive contrary instructions from one or more stockholders. This procedure reduces our printing and mailing costs. Stockholders who participate in householding will continue to be able to access and receive separate proxy cards. Upon written or oral request, we will deliver promptly a separate copy of the Notice, if applicable, the proxy statement and annual report, to any stockholder at a shared address to which we delivered a single copy of these documents. To receive a separate copy, or, if you are receiving multiple copies, to request that we only send a single copy of next year’s Notice proxy statement and annual report, as applicable, you may contact us as follows: PMV Pharmaceuticals, Inc. Attention: Corporate Secretary 400 Alexander Park Drive, Suite 301 Princeton, New Jersey 08540 Tel: (609) 642-6670 Street name stockholders may contact their broker, bank or other nominee to request information about householding. 6

TABLE OF CONTENTS

DIRECTORS AND CORPORATE GOVERNANCE Board Composition Our board of directors currently consists of seven members. Our directors are divided into three classes serving staggered three-year terms. Upon expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires. As a result of this classification of directors, it generally takes at least two annual meetings of stockholders for stockholders to effect a change in a majority of the members of our board of directors. The principal occupations and certain other information about the nominees and the additional members of our board of directors (including the skills and qualifications that led to the conclusion that they should serve as directors) are set forth below.

| Name                               |     | Class |     | Age |     | Position(s)                                               |     | Director 
    Since |     | Current 
    Term 
 Expires |     | Expiration 
    of Term 
  for Which 
  Nominated |
| Nominees for Director              |     |       |     |     |     |                                                           |     |          |     |         |     |            |
| Arnold Levine, Ph.D.               |     | II    |     |  85 |     | Class II Director                                         |     |     2013 |     |    2025 |     |       2028 |
| Charles M. Baum, M.D., Ph.D.(